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Introduction
A high incidence of upper respiratory tract infections (URTIs)
has been reported in athletes.7,19,21,22 These infections occur
during periods of intense training and after major competi-
tions such as ultramarathon events.28 To compete success-
fully in these ultramarathon events athletes need to train at
least daily, and often twice per day, and therefore it is possi-
ble that chronic suppression of immune function may result
from the cumulative acute post-exercise suppression of each
successive exercise bout.14 The increase in infection risk
after participation in intense exercise provides a model to
study the efficacy of agents that may enhance resistance to
such infections.19,22
A number of studies have investigated the impact of nutri-
tional supplements on immune status and URTIs, with con-
flicting results being reported.1,18,22  However, none have
investigated the role of an L-methionine combination supple-
ment (L-methionine, vitamin B6, vitamin B12, folic acid and
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Abstract
Objective. To evaluate whether supplementation with an
L-methionine combination would reduce the incidence of
upper respiratory tract symptoms (URTS) and improve
performance in ultramarathon runners.  
Design. A double-blind placebo-controlled study.
Setting. Twenty-one ultramarathon runners (17 males, 4
females) preparing for participation in an 87.3 km 
ultramarathon.  
Interventions. L-methionine combination supplement (L-
methionine, vitamin B6, vitamin B12, folic acid and magne-
sium) or placebo containing potato starch.
Main outcome measures. Incidence of URTS was
recorded during the runner's preparation for an ultrama-
rathon race (75 days) and recovery from the same (75
days). CD4+, CD8+ cell counts and ratios were measured
pre race, immediately post race and 75 days post race.
VO2max and endurance fitness (percentage VO2max at 
4 mmol-1 lactate concentration) were measured during the
preparation period for the race.  
Results. During the preparation period the incidence of
URTS was 36% in the supplement group and 80% in the
placebo group (p = 0.08).  The incidence of URTS during
the 3 weeks post race was 27% in the supplement group
and 40% in the placebo group (p = 0.65).   The
CD4+/CD8+ cell ratios were not significantly different
between groups.  Endurance fitness prior to the race and
race times were not significantly different.
Conclusions. Although the findings of the current study
show that an L-methionine combination supplement did
not reduce the incidence of URTS or improve perfor-
mance in ultramarathon runners, benefits may be found
with a more detailed investigation using larger sample
sizes and immunosuppressed athletes.
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magnesium) on symptoms of URTIs in athletes.  Results
from a study investigating the effects of an L-methionine
combination supplement in HIV+ patients propose that it
slows the rate of decline in CD4+ cell counts and improves
the viral load levels after 3 months.32 The 5 active substances
(L-methionine, vitamin B6, vitamin B12, folic acid and magne-
sium) in the supplement participate in the maintenance of
glutathione status and have been shown to elevate intracel-
lular glutathione.16,31,33
Magnesium is an essential co-factor for the enzyme
methionine adenosyl transferase, which forms S-adenosyl-
methionine (SAM) from L-methionine.16 SAM can provide a
methyl group to a variety of substances and S-adenosylho-
mocysteine (SAH) is formed as a product.16 SAH can then
form L-homocysteine and adenosine.16 Folate and vitamin
B12 are essential co-factors for the remethylation of L-homo-
cysteine to L-methionine.  SAH can be converted by 3 enzy-
matic steps (which involve vitamin B6) to L-cysteine and
subsequently to glutathione.16 It is glutathione (a major
endogenous antioxidant) that has been found to have antivi-
ral activity and to be important as a mediator of normal
immune responsiveness.9,11 Strenuous exercise has been
shown to deplete tissue glutathione content12,13 and increase
the risk of URTIs.19
In addition to studying the effects of antioxidant supple-
ments on immune status and URTIs, a number of studies
have also investigated their role in performance.23,25,30,34
Although several studies have indicated that supplementa-
tion with vitamins E and C decreases exercise-induced
oxidative stress, there is little evidence that antioxidant sup-
plementation can improve human performance.24 However,
one well-designed study has reported an improvement in
muscular endurance following supplementation with N-
acetylcysteine (a glutathione precursor).25
Therefore, the purpose of this study was to use a double-
blinded, placebo-controlled design to determine firstly
whether supplementation with an L-methionine combination
supplement would decrease the incidence of symptoms of
URTIs in runners during their preparation and recovery from
an ultramarathon race, and secondly whether this supple-
ment would impact on their endurance fitness prior to the
ultramarathon and ultimately how it would influence their per-
formance in the ultramarathon.
Methods
Subjects
Prior to commencement of this study, ethics approval was
obtained from the Committee for Research on Human
Subjects of the University of the Witwatersrand.
Thirty healthy well-trained, ultramarathon runners (20
males and 10 females) preparing for participation in an 87.3
km ultramarathon race  volunteered to participate in this
study after providing informed consent.  Runners reported
having run on average 5 ± 3 (mean ± SD) ultramarathons,
with the best marathon performances averaging 3.17 ± 0.22
(mean ± SD) hours.
Subjects were paired according to VO2max levels, proposed
training programmes and gender.  Each member of a pair
was randomly assigned to either the supplementation
(experimental) or placebo group.
During the training period prior to the race 5 subjects with-
drew from the study due to orthopaedic injuries while 4 sub-
jects failed to comply with testing procedures and were
asked to discontinue with the study.   The dropout rate in the
current study (N = 9) was high but comparable with that
reported in other studies (N = 8).22,23 The sample was finally
fixed at 21 subjects, which included 4 females and 17 males
(N = 11 supplement and N = 10 placebo).  Of the final 21
subjects, 6 subjects in each group remained paired accord-
ing to the criteria stated above.
Performance measurements
The subjects were required to report to the testing laborato-
ry situated at an altitude of 1 330 m with an average baro-
metric pressure of 656 mmHg and a room temperature
regulated at 20 - 22ºC on day 1 (75 days before the race).
All subjects were tested within the same week.  The subjects
were familiarised with the testing equipment and procedures
prior to the commencement of testing. Subjects were asked
not to train for 12 hours prior to all the testing, not to train
hard (≤ 70% of maximal heart rate) on the day before testing
and not to consume any food or caffeinated drinks 3 hours
prior to testing.
Each subject was asked to run on a motorised treadmill
(Quinton Q65 series 90, Quinton Instrument Co., Bothell,
WA, USA).  Maximal aerobic capacity (VO2max) was mea-
sured using a continuous model adapted from the Astrand
protocol.15 The criteria for VO2max included subjects obtaining
2 of the following 3 criteria: a plateau in VO2 despite an
increase in workload,  a respiratory exchange ratio in excess
of 1.10, and blood lactic acid levels > 8 mmol.-1.6 Oxygen
consumption and ventilation were determined using the
MedGraphics CardiO2 combined VO2/ECG exercise system
(Medical Graphics Corporation, St. Paul, MN, USA).   
The lactate concentration for capillary blood was mea-
sured using the Accusport Analyzer (Boehringer Mannheim,
BmbH, Mannheim, Germany) and the BM-Lactate test strips.
Blood samples were collected during the last 30 s of each
workload during the VO2max test.  Capillary blood was
obtained by pricking a fingertip with a lancet.  On average 5
blood samples were obtained during each VO2max test.
Lactate concentrations at each workload were plotted and an
exponential curve was fitted using Table Curve 2D (Jandel
Scientific Software, San Rafael, CA, USA).  The percentage
VO2max at 4 mmol.-1 lactate was calculated and used as a
measure of endurance fitness.8,10 The above tests were
repeated again 14 days before the race.  All tests were again
performed within 1 week and at the same time of the day as
the first testing session.
In addition to endurance fitness, race time (as obtained
from official race records) was also used as a measure of
performance.
Supplementation
Supplementation started on day 2 and ended on day 150 of
the study.  The supplement (Bio Boost) and placebo were
supplied by Biomox Pharmaceuticals in capsule form and
administered orally.  The active ingredients administered in
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the supplement were: L-methionine 405 mg, folic acid 0.36
mg, vitamin B6 1.575 mg, vitamin B12 0.01125 mg, magne-
sium 135 mg.  The placebo contained potato starch (500 mg
per day) and no active ingredients.  From day 1 to day 7 (first
week of the study) and day 76 to day 83 (first week after the
race), subjects ingested 3 capsules twice a day (1 215 mg of
L-methionine, 1.08 mg folic acid, 4.725 mg vitamin B6,
0.03375 mg vitamin B12 and 405 mg magnesium) on an
empty stomach.  After these 2 periods (i.e. days 8 - 75 and
days 84 - 151) subjects were instructed to ingest 2 capsules
twice a day (810 mg L-methionine, 0.72 mg folic acid, 3.15
mg vitamin B6, 0.0225 mg vitamin B12 and 270 mg magne-
sium) on an empty stomach.  This schedule of ingestion was
prescribed by the supplier and manufacturer of the product
based on trials done on individual patients by the original for-
mulators (unpublished data) and was the same for the 2
groups.
Incidence of upper respiratory tract symp-
toms (URTS)
The incidence of symptoms of URTIs was recorded daily by
the subjects in a logbook provided which was based on the
questionnaire used in the studies investigating the effect of
glutamine or placebo ingestion on the incidence of infections
in runners.2 The adapted questionnaire was not validated
prior to use in this study.  Subjects were asked to record all
symptoms reported under the headings of cold, cough, sore
throat, running nose, sneezing and influenza and for how
long the symptoms were present.2 A subject was considered
to have an illness when he or she reported 3 symptoms for
a cold (cough, sore throat, running nose, sneezing) or
influenza (fever, aches and pains in joints or muscles, cough,
sore throat) such that they did not train or such that they con-
sulted a doctor for treatment.  Other illnesses, e.g. diarrhoea
and vomiting were not included.  The incidence of the symp-
toms and the duration of the symptoms (number of days the
symptoms were present) was calculated. Recordings were
controlled monthly with each visit to the laboratory to collect
more supplements and telephonically when booking each
appointment.  The diagnosis was not verified by clinical
examination although patients did indicate if they had seen a
medical doctor for treatment.
Blood sampling
CD4+ and CD8+ measurements were taken on day 75 (18
hours pre-race), day 76 (10 min post race) and on day 150.
With each sampling session blood was drawn from a forearm
vein into evacuated collection tubes.  The blood for the CD4+
and CD8+ measurements was collected in a 4.5 ml vacuette
(K3E EDTA K3, Greiner Labortechnik). Following process-
ing, specimens were packed in a refrigerated container and
transported to a central laboratory where they were analysed
within 18 hours of collection.  The proportions of T-cells
(CD4+ and CD8+) were measured using flow cytometry
(FACSCount, Becton Dickinson, San Jose, USA) which
includes the use of fluorescent labelled monoclonal antibod-
ies to cell surface antigens as previously described.26 All
concentrations were corrected for changes in plasma volume
post race.3
Training
All training information (running distance, time and intensity)
and injuries were recorded weekly in a standardised training
logbook given to the subjects.  The training logbooks were
adapted from those used in a study investigating the effects
of lactate-correlated training on running performance but
were not validated prior to use in this study.27
Nutrition
The subject's compliance with capsule use was recorded
daily in a logbook given to the subjects.  In addition, every 4
weeks subjects were asked to indicate how many capsules
were left before they received a new bottle of capsules.
Subjects were asked not to take any other vitamin and min-
eral supplements for the duration of the study.  Dietary habits
were evaluated from a 24-h dietary recall.  As a method of
reporting food intake the 24-h dietary recall questionnaire
has been validated against weighted 7-day food records.4
The dietary recall was completed daily by each subject to
ensure that subjects did not change their diets over the dura-
tion of the study.  Subjects were taught how to keep accurate
food records prior to commencement of the study.  Nutrient
content of each athlete's reported daily dietary intake was
assessed (macro and micro nutrients) using a computerised
dietary analysis system (Food Fundi Analyzer 2,
Professional Penta Medical Systems, Johannesburg, South
Africa).   
Statistical analysis
Data are expressed as means ± standard deviation (SD).
The analysis of changes in all blood measurements (CD4+,
CD8+ cell counts and ratio) was done using an analysis of
variance (ANOVA) procedure for repeated measures to esti-
mate main effects (group or time) and an interaction effect
(group x time) followed by a Tukey-Kramer multiple compar-
isons post-hoc test. For all other dependent variables the
unpaired t-test was used to test for the significance of the dif-
ferences between the groups.  A Fisher's exact probability
test was used to analyse a 2 x 2 contingency table for being
sick and not being sick (incidence of illness).  The level of
significance used was p ≤ 0.05.  A post hoc power analysis
showed the power for the following statistical tests: repeated
measures ANOVA (time effect power = 0.990, time x group
effect power = 0.153); unpaired t-tests (%VO2max @ 4mmol.-1
lactate power = 0.7968, duration of symptoms power =
0.4264) and Fisher's exact test (incidence of illness power =
0.3196).
Results
Physical characteristics
The physical and performance characteristics of the subjects
are given in Table I.  There was no significant group differ-
ences on any of the parameters measured.  It should be
noted that based on the race finishing times and VO2max val-
ues the runners would be classified as non-elite, experi-
enced and well-trained runners.20
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Incidence of upper respiratory tract symp-
toms (URTS)
The incidence of symptoms of URTIs in both groups during
the 75 days of preparation is shown in Table II.  During the
preparation period the percentage of symptoms of URTIs
(p = 0.08) and the duration of symptoms per illness incident
(p = 0.13) was not significantly different. The incidence of
URTS (p = 0.65) and duration of symptoms (p = 0.55) during
the 3 weeks following the race was not significantly different.
During the entire 75 days of recovery from the race the inci-
dence of URTS (p = 1.00) and duration of symptoms was
also not significantly different (p = 0.66).
Training programmes
There was no significant difference in the total training dis-
tance completed in preparation for the race, with the supple-
ment group completing 896 ± 235 km and the placebo group
892 ± 192 km.  
Physiological responses
Aerobic capacity variables monitored during preparation for
the race are shown in Table III.  The supplement group had
a significantly greater percentage VO2max at 4 mmol.-1 lactate
concentration (endurance fitness) than the placebo group
12 - 14 days prior to the start of the race.  However the mean
change in endurance fitness over the 75-day training period
was not significantly different. No significant differences in
race times were found, with the supplement group running
8.45 ± 1.54 hours and the placebo group 8.51 ± 1.08 hours.  
Prior to the start of the race (18 hours) no significant dif-
ferences were noted in the immune cell subsets (Figs 1 and 2).
CD4+ cells decreased significantly in both groups imme-
diately post race (Fig. 1) while the CD8+ cells only
decreased significantly in the supplement group immediate-
ly post race (Fig. 2).  The CD4+/CD8+ ratio did not change
significantly immediately post race in both groups or 75 days
post race (Fig. 3).  No significant differences were noted
between the groups for the CD4+, CD8+ cell counts and
ratios.
Nutrition
The subjects were all Caucasian, from the same socio-eco-
nomic background and no significant differences (p > 0.05)
between groups were observed for nutrient analysis of food
records across all time periods.  The average daily energy
intake for all was 13 600 ± 4 009 kJ.day-1, with carbohydrate,
fat and protein respectively comprising 58 ± 11.5%, 24.2 ±
6.3% and 15.4 ± 3.5% of the daily caloric intake.   
Discussion
The essential finding of this study was that 150 days of sup-
plementation with an L-methionine combination had no sig-
nificant effect on the incidence of URTS and race
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TABLE I. Physical and performance characteristics of
the subjects*
Supplement Placebo group 
group (N = 11) (N = 10) P-value
Age (years) 36 ± 3 35 ± 8 0.74
Height (m) 1.73 ± 0.09 1.75 ± 0.05 0.67
Mass (kg) 69.5 ± 10.7 68.9 ± 8.4 0.89
VO2max 
(ml.kg-1.min-1) 58 ± 8 57 ± 7 0.78
Best standard 
marathon time
(hours) 3.18 ± 0.25 3.16 ± 0.20 0.84
Best Comrades 
marathon (90 km) 
time (hours) 8.37 ± 1.09 8.27 ± 1.07 0.83
*Values are means ± SD. 
Table III. Aerobic capacity variables monitored during
preparation for the race
June
Parameters April (12-14 days prior to the race)
VO2max (ml.kg
-1.min-1)
Supplement 58 ± 8 59 ± 7
Placebo 57 ± 7 58 ± 7
Percentage VO2max
at 4 mmol.-1 lactate 
concentration
Supplement 86 ± 4 87 ± 4*
Placebo 84 ± 5 83 ± 5
Values are means ±SD; N = 11 supplement and N = 10 placebo subjects.
Difference between absolute values: April P > 0.05;*June P < 0.05
Difference between delta values (June - April); P = 0.08 for percentage VO2max
at 4 mmol.-1 lactate concentration; VO2max P = 0.84.
TABLE II. Percentage of symptoms of URTIs and duration of symptoms during the study
Subjects with % symptoms P-value Mean duration of P-value
Subject/ group symptoms/total group of URTIs % symptoms symptoms (days) mean duration of symptoms
Preparation Supplement 4/11 36 3 ± 1  
(0 - 75 day) Placebo 8/10 80 0.08 5 ± 3  0.13
3 weeks Supplement 3/11 27 4 ± 2 
post-race 0.65 0.55
(76 - 97 day) Placebo 4/10 40 6 ± 4  
During Supplement 6/11 55 6 ± 4
recovery 1.00 0.66
(76 -150 day) Placebo 6/10 60 5 ± 3  
performance in ultra-endurance runners.
There is evidence for the role of nutrient supplements in
modulating the incidence of URTIs post race.  Peters et al.22
examined the effect of supplementation with vitamin C (an
antioxidant) on the URTIs of ultramarathon runners compet-
ing in the same race in 1990 and showed that 21 days of vit-
amin C supplementation reduced the post-race incidence of
URTIs.  Glutamine (an amino acid) supplementation immedi-
ately post race and 2 hours post race has also been shown
to reduce the incidence of infections within 7 days post race
in runners competing in marathon and ultramarathon
events.2 
The results of the current study show that supplementa-
tion with an L-methionine combination did not influence the
incidence of URTS during the training for or recovery from an
ultramarathon race in runners nor did it reduce the duration
of symptoms.  One main difference between the above two
studies and this study is the use of larger sample sizes (27 -
88 subjects).  Owing to the long duration of the study 9 sub-
jects withdrew, which is similar to what has been reported in
other studies.22,23 The small sample size used in the current
study could influence the acceptance or rejection of the null
hypothesis.
In addition to the results on URTS, we did not find any sig-
nificant differences in the CD4+ and CD8+ cell counts or
CD4+/CD8+ cell ratios post race.  This immune marker was
used as an L-methionine combination supplement (supple-
ment with the same combination as used in this study but at
a higher concentration) and N-acetylcysteine (NAC) treat-
ment, both of which are glutathione precursors and have
been shown to slow the decrease of CD4+ cell counts in
HIV+ patients.12,32 The stress of prolonged exhaustive exer-
cise has been shown to lower the CD4+ cell counts and
CD4+ to CD8+ cell ratio in athletes.1 This marker has also
been used in other studies which have examined the effect
of supplementation on the immune system post marathon
and it has been suggested that a ratio of CD4+/CD8+ cells
below 1.5 is below normal and may be a cause of and an
indicator of immunosuppression in athletes.17,29
There are, however, several factors which might account
for the negative findings regarding the immune responses
measured in this study.  Firstly no CD4+/CD8+ cell mea-
surements were taken during the training period in which the
largest difference in the incidence of URTS was noted
between the supplement and placebo groups.  Secondly,
enumeration of circulating cells does not provide as conclu-
sive information on immune function or activation of cells as
does examining direct measurements of cell function.35
Thirdly, the reported symptoms of URTIs by the subjects
were not verified by clinical examination which would have
confirmed the presence of an infection.  Fourthly, including a
non-exercising control group would have strengthened the
findings of the current study as the incidence of symptoms in
the general population could have been compared with that
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Fig. 1. CD4+ cell measurements in both groups pre-race,
immediately post-race and 12.5 weeks post-race (** p <
0.001 for the supplement group and * p < 0.001 for the
placebo group immediately post-race when compared with
pre-race values). (Values are means ± SD; N = 11 supple-
ment and N = 10 placebo subjects).
Fig 2. CD8+ cell measurements in both groups pre-race,
immediately post-race and 12.5 weeks post-race (* p < 0.01
for the supplement group immediately post-race when
compared with pre-race values). (Values are means ± SD;
N = 11 supplement and N = 10 placebo subjects).
Fig 3. CD4+/CD8+ ratio measurements in both groups pre-
race, immediately post-race and 12.5 weeks post-race.
(Values are means ± SD; N = 11 supplement and N = 10
placebo subjects).
found in the exercising group.  Furthermore it has been sug-
gested that the CD4+ T-cell system may be negatively affect-
ed not only by suboptimal but also by supraoptimal
glutathione levels.12 Therefore further investigation is need-
ed to not only analyse the activity of the immune cells in
response to L-methionine combination supplementation but
also in relation to glutathione levels.
In addition to the role of antioxidant supplements in
immune function, previous studies have also examined their
effects on performance due to growing evidence indicating
that radicals and other reactive oxygen species may con-
tribute to muscular fatigue.24 Conflicting results have been
presented from these studies which may be due to agent
administration, dosage and the pattern of muscular activity
used to induce fatigue. 
Weight et al.34 found that 3 months of vitamin and mineral
supplementation had no effect on oxygen consumption,
blood lactate turnpoint, peak treadmill running speed and 
15 km time trial performance in 30 well-trained runners.
Time to exhaustion at 70% VO2max was not reduced in 11
highly trained male triathlon athletes after 4 weeks of sup-
plementation with vitamin E, coenzyme Q10, cytochrome C
and inosine.30 Reid et al.,25 however found an improvement in
muscular endurance (during low frequency stimulation) fol-
lowing treatment with 150 mg N-acetylcysteine (a glu-
tathione precursor). N-acetylcysteine has been shown to
increase glutathione levels in plasma and bronchoalveolar
lavage fluid in humans; however its use is limited due to a
number of side-effects.25 In the present study no change in
VO2max and endurance fitness (percentage VO2max at 4 mmol.-1
lactate) was found after 75 days of supplementation.  The
finding that performance in the race (87.3 km) was unaltered
by supplementation tends to confirm the laboratory findings.
These findings are therefore in keeping with the majority of
studies showing that long-term supplementation with antiox-
idant nutrients does not improve human performance.5,24,34
Conclusions
In summary, although the findings of the current study do not
support the use of an L-methionine combination supplement
in reducing the incidence of URTS in ultramarathon runners,
the positive results found with HIV+ patients does suggest
that this supplement has a role to play in immune function.
Future studies will need to be conducted with larger sample
sizes, will need to include measures of immune function and
glutathione levels, and will need to be directed at athletes
who are shown to be immunosuppressed such as over-
trained athletes or patients who present with specific disease
states in which glutathione or its precursors are depleted.
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